Celaid Therapeutics
Celaid Therapeutics is a biotech company that develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders.
Celaid Therapeutics is a biotech company that develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders.
Celaid Therapeutics has raised $3.6M across 1 round. Its most recent round was a Series B of $3.6M in Oct 2025. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Celaid Therapeutics is featured in
Similar companies
Bionto is a biotech startup that is shaping the future of medicine and healthcare through its groundbreaking bio-iontronics technology.
Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients.
Reprogenix is a groundbreaking medical technology firm
Rion Vet mission is to drive the regenerative medicine revolution.
Oncolab is developing a technology that reduces systemic toxicity and enhances therapeutic efficacy.
Modulight Bio develops an optogenetic platform intended for the treatment of neurological disorders.
Nomax Therapeutics develops a healthcare technology platform to provide therapies for neurodegenerative diseases.
Gregor Diagnostics is a molecular diagnostics company developing a screening test technology for prostate cancer.
Gut Brain Axis Therapeutics is a biotechnology company that offers treatment for Autism Spectrum Disorder with microbial transplant therapy.
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.
iOrganBio is a pioneering cell production platform.
GRIT Biotechnology develops tumor infiltration lymphocytes immunotherapy for solid tumors.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.